Goldman Sachs Group is a leading global investment banking, securities, and investment management firm that provides a wide range of financial services to a diverse client base, including corporations, financial institutions, governments, and individuals. The company engages in various activities, including financial advisory services, underwriting of capital market transactions, asset management, and market making in securities and commodities. It is known for its expertise in mergers and acquisitions, risk management, and investment strategy, leveraging its extensive research capabilities and global reach to deliver innovative solutions in an ever-evolving financial landscape.
Goldman Sachs and Morgan Stanley are two of the leading investment bankers on Wall Street posting double digit revenue growth in Q4, but which has more upside?
Goldman Sachs analyst Salveen Richter highlights potential benefits for biopharma from 340B reforms, while Medicaid cuts could pose risks for companies with significant drug exposure.
Goldman Sachs downgrades MGY and OXY, reinstates coverage on EXE. MGY's outperformance reflected in current stock price, OXY's leverage a concern. EXE receives Buy rating with potential 18% upside.
Goldman Sachs analyst Bonnie Herzog maintains a Buy rating on Colgate-Palmolive, with a price target of $106. Despite Q4 EPS of $0.91 exceeding expectations, organic sales growth of 4.3% fell short.
VF Corp delivered a strong Q3 performance, exceeding expectations, with significant improvements across all regions. Goldman Sachs analyst Brooke Roach reiterated a Neutral rating, raising the price target to $25.
Ray Dalio, founder of Bridgewater Associates, called for urgent measures to address the mounting U.S. federal debt crisis during an interview on The All-In Podcast, emphasizing the need to reduce the deficit to 3% of gross domestic product from its current level of nearly 7%.
